TIDMAREC
Arecor Therapeutics PLC
15 May 2023
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
TETRIS PHARMA LAUNCHES OGLUO (R) IN DENMARK AND NORWAY
A new treatment option for severe hypoglycaemia for children and
adults living with diabetes
Launches build on continued roll out in Austria, Germany and the
UK
Cambridge, UK, 15 May 2023: Arecor Therapeutics plc (AIM: AREC),
the biopharmaceutical company advancing today's therapies to enable
healthier lives, announces that subsidiary company, Tetris Pharma
Ltd, has today launched Ogluo(R) (glucagon prefilled autoinjector
pen) in Denmark and Norway as a treatment for severe hypoglycaemia
in adults, adolescents, and children aged two years and over living
with diabetes mellitus.
See full Tetris Pharma announcement below:
15 May 2023 - Tetris Pharma Ltd ("Tetris Pharma" or "the
Company"), a subsidiary of biopharmaceutical company, Arecor
Therapeutics plc (AIM: AREC), today announces the launch of
Ogluo(R) (glucagon prefilled autoinjector pen) in Denmark and
Norway as a treatment for severe hypoglycaemia in adults,
adolescents, and children aged two years and over living with
diabetes mellitus.
Ogluo(R) is a ready-to-use, ambiently stored, preparation of
glucagon in an auto-injector for patients within the licenced
indication living with diabetes suffering from severe
hypoglycaemia(1) . Hypoglycaemia is a common and serious
complication of diabetes, particularly affecting people with
diabetes on insulin treatment. It is characterised by abnormally
low blood sugar levels, which can lead to cognitive impairment and
in some severe cases, seizures, loss of consciousness, coma and
even death. It can have a profound effect on the everyday lives of
people with diabetes and their caregivers(2) .
Ogluo(R) pricing has today been published in both Denmark and
Norway allowing patients to access this rescue medication, full
prescribing information can be found here . Ogluo(R) is also
available in Austria, Germany and the UK. Tetris Pharma is working
to commercialise Ogluo(R) in core European markets as part of a
pan-European commercialisation programme.
Dr Shafiq Choudhary, European Managing Director of Tetris Pharma
said : "With over half a million people estimated to be living with
diabetes in Denmark and Norway alone(3) , the launch of Ogluo(R)
gives patients living with diabetes an alternative ready to use,
ambient stored glucagon that can be kept by the patients' side,
giving their families and those around them the confidence to
manage severe hypoglycaemic events. The launch extends our
commercial footprint and pan-European presence."
1. Ogluo SmPC
2. Amiel, S.A. The consequences of hypoglycaemia. Diabetologia 64, 963-970 (2021). https://doi.org/10.1007/s00125-020-05366-3
3. (IDF Atlas 10(th) Edition 2021 Diabetes report
https://diabetesatlas.org/data/en/country/148/no.html /
https://www.diabetesatlas.org/data/en/country/56/dk.html ) Access
Date:9/5/23
Enquiries:
Tetris Pharma
Dr Shafiq Choudhary +44 (0)1628 337579
Notes to Editors
Tetris Pharma, a subsidiary of Arecor Therapeutics plc, is a
commercial-stage specialty pharmaceutical company with expertise in
registering, marketing, sales and the distribution of speciality
hospital products across the UK and Europe. Our experienced team
has a proven history of building and growing sales. Having secured
distribution rights for already licensed products across Europe, we
have a portfolio of niche injectable products including Ogluo(R) ,
a ready-to-use glucagon for emergency use to treat hypoglycaemia.
We collaborate with partners to provide patients with effective
treatments and quality healthcare by ensuring we deliver
accountability, partnership and performance.
For further information, please visit tetrispharma.com
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060
Officer Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD Tel: +44 (0) 20 7886 2500
and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
Consilium Strategic Communications Tel: +44 (0) 20 3709 5700
Chris Gardner, David Daley, Lindsey Email: arecor@consilium-comms.com
Neville
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
company transforming patient care by bringing innovative medicines
to market through the enhancement of existing therapeutic products.
By applying our innovative proprietary technology platform,
Arestat(TM), we are developing an internal portfolio of proprietary
products in diabetes and other indications, as well as working with
leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat(TM) platform is supported by an
extensive patent portfolio.
For further details please see our website, www.arecor.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEAKSLFFEDEFA
(END) Dow Jones Newswires
May 15, 2023 02:00 ET (06:00 GMT)
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From Apr 2024 to May 2024
Arecor Therapeutics (LSE:AREC)
Historical Stock Chart
From May 2023 to May 2024